期刊
JOURNAL OF IMMUNOLOGY
卷 186, 期 12, 页码 6822-6829出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1003682
关键词
-
类别
资金
- National Institutes of Health [R01CA115880, R01CA84232, R01EY016486, T32 GM066706, R25-GM55036]
- Graduate Assistance in Areas of National Need predoctoral fellowship
- Rotterdamse Vereniging Blindenbelangen
- Stichting Blindenhulp
- Stichting Blinden-Penning
- Stichting Dondersfonds
- Stichting Nelly Reef Fund
- Gratama Stichting
- Stichting Admiraal van Kinsbergen Fonds
- Foundation De Drie Lichten fellowships
- Deutsche Forschungsgemeinschaft [DFG-SFB643 (C8)]
Programmed death ligand 1 (PDL1, or B7-H1) is expressed constitutively or is induced by IFN-gamma on the cell surface of most human cancer cells and acts as a molecular shield by protecting tumor cells from T cell-mediated destruction. Using seven cell lines representing four histologically distinct solid tumors (lung adenocarcinoma, mammary carcinoma, cutaneous melanoma, and uveal melanoma), we demonstrate that transfection of human tumor cells with the gene encoding the costimulatory molecule CD80 prevents PDL1-mediated immune suppression by tumor cells and restores T cell activation. Mechanistically, CD80 mediates its effects through its extracellular domain, which blocks the cell surface expression of PDL1 but does not prevent intracellular expression of PDL1 protein. These studies demonstrate a new role for CD80 in facilitating antitumor immunity and suggest new therapeutic avenues for preventing tumor cell PDL1-induced immune suppression. The Journal of Immunology, 2011, 186: 6822-6829.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据